OPTIMIZE Study Results Highlight Efficacy and Safety of XPHOZAH in Reducing Phosphate Levels in Patients with End-Stage Renal Disease.
Post-Hoc Analysis of the Optimize Study Supporting Xphozah (Tenapanor) to be Presented at the National
Chicago, IL - April 25, 2023 - Aurinia Pharmaceuticals Inc. (Aurinia) announced today that a post-hoc analysis of the Optimize study, which evaluated the efficacy and safety of Xphozah (tenapanor) in patients with focal segmental glomerulonephritis (FSGS), will be presented at the National Kidney Foundation's 2023 Spring Clinical Meetings.
The post-hoc analysis, titled "Tenapanor Treatment Effect in Patients with FSGS: A Post-Hoc Analysis of the Optimize Study," will be presented by Dr. David N. Wilson, a renowned nephrologist and Professor of Medicine at the University of Alabama at Birmingham. The analysis will explore the treatment effect of Xphozah in patients with FSGS, a rare and debilitating kidney disease.
The Optimize study, which was conducted in 2022, demonstrated that Xphozah significantly reduced proteinuria (excess protein in the urine) in patients with FSGS, compared to placebo. The study also showed that Xphozah was well-tolerated and had a favorable safety profile.
"We are excited to share the results of this post-hoc analysis with the nephrology community," said Dr. Peter L. Nelson, Aurinia's Chief Medical Officer. "The data from the Optimize study and this post-hoc analysis further support the potential of Xphozah to make a meaningful difference in the lives of patients with FSGS."
The National Kidney Foundation's 2023 Spring Clinical Meetings will take place from April 26-29, 2023, in Las Vegas, NV. The presentation of the post-hoc analysis will be available for attendees to view and discuss.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company dedicated to delivering innovative therapies that improve the lives of patients with rare and debilitating diseases. The company's lead product, Xphozah (tenapanor), is an oral, small-molecule inhibitor of the sodium-hydrogen exchanger 3 (NHE3) and is currently approved in the United States and the European Union for the treatment of FSGS. For more information, please visit Aurinia's website at www.auriniapharma.com.